BUZZ-CSPC Pharmaceutical jumps most in eight months on hypertension drug approval** Shares of CSPC Pharmaceutical Group 1093.HK jump 9.2% to HK$9.99, on course for biggest one-day pct gain since June 6
** Stock on track to snap two straight sessions of falls
** CSPC says its product Clevidipine Injectable Emulsion for treatment of hypertension has obtained drug registration approval from China's National Medical Products Administration
** Says approval will enrich its product pipeline in the therapeutic area of cardiovascular disease, enhance its competitiveness while addressing clinical needs for medications used in hypertensive emergencies
** YTD, stock up 17.3%, Hang Seng Biotech Index .HSBIO up 6.4%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments